Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4

Maxim Group analyst Jason McCarthy initiates coverage on Telomir Pharmaceuticals (NASDAQ:TELO) with a Buy rating and announces Price Target of $4.